Thodou E, Kontogeorgos G, Kyrodimou E, Salla H, Ramyar L, Vamvassakis E, Piaditis G, Anagnostopoulos N, Tzanis S, Levedis A, Rologis D, Asa S L
Department of Pathology, G. Gennimatas, General Hospital of Athens, Greece.
J Endocrinol Invest. 1999 Oct;22(9):671-80. doi: 10.1007/BF03343628.
The purpose of this study was to detect in vitro growth hormone (GH) and prolactin (PRL) secretion from adenomas clinically associated with GH or PRL hypersecretion. The reverse hemolytic plaque assay (RHPA) was applied in order to reveal possible differences among various morphologic adenoma types, and to examine the inhibitory effects of octreotide on GH release as well. The 20 surgically resected pituitary adenomas studied included 15 from acromegalic patients and 5 from patients with hyperprolactinemia. All adenomas were diagnosed by histology, immunocytochemistry and electron microscopy. Among tumors associated with acromegaly, 5 were densely granulated (DG), 5 were sparsely granulated (SG) somatotroph (SM) adenomas, 2 were mammosomatotroph (MSM) and 3 mixed somatotroph-lactotroph cell (mixed SM-LT) adenomas; tumors causing hyperprolactinemia included 4 lactotroph (LT) adenomas and 1 mixed SM-LT adenoma. GH release assessed by the RHPA corresponded to in vivo hormone secretion and to tissue immunoreactivity. Statistical analysis showed significant differences among all morphologic types of SM adenomas, exclusive of SG-SM adenomas compared to mixed SM-LT adenomas. The mean plaque size in DG-SM and MSM adenomas was significantly greater than that of SG-SM and mixed SM-LT adenomas, indicating higher GH secretion by the former two types during the same incubation time. PRL secretion was documented in 2 mixed SM-LT adenomas. Plaques for PRL, but not for GH were formed in all LT adenomas. In all SM and LT adenomas, cells producing large plaques represented a minority of the plaque-forming cell population, however, they accounted for the largest part of the total plaque area, thus the largest part of hormone secretion. Octreotide effects on GH release were studied in 6 adenomas by the RHPA. Octreotide treatment induced a rapid and significant reduction in GH secretion by SM cells in vitro, with a selective effect on high-secreting cells.
本研究的目的是检测临床上与生长激素(GH)或催乳素(PRL)分泌过多相关的腺瘤的体外生长激素和催乳素分泌情况。应用反向溶血空斑试验(RHPA)以揭示不同形态学类型腺瘤之间可能存在的差异,并检测奥曲肽对GH释放的抑制作用。所研究的20例手术切除的垂体腺瘤中,15例来自肢端肥大症患者,5例来自高催乳素血症患者。所有腺瘤均通过组织学、免疫细胞化学和电子显微镜检查确诊。在与肢端肥大症相关的肿瘤中,5例为密集颗粒型(DG)、5例为稀疏颗粒型(SG)生长激素细胞(SM)腺瘤,2例为泌乳生长激素细胞(MSM)腺瘤,3例为混合生长激素-催乳素细胞(混合SM-LT)腺瘤;导致高催乳素血症的肿瘤包括4例催乳素细胞(LT)腺瘤和1例混合SM-LT腺瘤。通过RHPA评估的GH释放与体内激素分泌及组织免疫反应性相符。统计分析显示,除SG-SM腺瘤与混合SM-LT腺瘤相比外,所有形态学类型的SM腺瘤之间均存在显著差异。DG-SM和MSM腺瘤的平均空斑大小显著大于SG-SM和混合SM-LT腺瘤,表明在前两种类型腺瘤中,在相同孵育时间内GH分泌量更高。在2例混合SM-LT腺瘤中记录到PRL分泌。所有LT腺瘤中均形成了PRL空斑,但未形成GH空斑。在所有SM和LT腺瘤中,产生大空斑的细胞占空斑形成细胞群体的少数,然而,它们占总空斑面积的最大部分,因此也是激素分泌的最大部分。通过RHPA在6例腺瘤中研究了奥曲肽对GH释放的影响。奥曲肽治疗在体外可迅速且显著降低SM细胞的GH分泌,对高分泌细胞具有选择性作用。